IL2 and melanoma: Molecules were administered either as single-agent therapeutics (Supplementary Fig. 3a) or in combination with TA99 antibody (which targets surface Trp1 on melanocytes), which is widely used in combination with IL-2 in the poorly immunogenic B16 melanoma model36 (Fig. 3b).